ISOPP CAPhO 2025 Symposium: Pre-therapeutic Pharmacogenomic Testing to Prevent Adverse Drug Reactions: Experiences from the U-PGx PREPARE Study and Beyond

Retrospective, prospective and naturalistic studies all provide compelling evidence that genetic variation affects the way people respond to drugs. Currently, reactive, and pre-therapeutic single-gene PGx tests are increasingly applied in clinical practice for several indications, such as DPYD testing in oncology. Moreover, specific recommendations on how to tailor drug treatment based on genetic test results are available from the Dutch Pharmacogenetics Working Group (DPWG) and Clinical Pharmacogenetics Implementation Consortium (CPIC) for a large number of drugs. In addition to pre-therapeutic testing for a single gene, pharmacogenomic panel-based testing represents a new model for precision medicine. While several small studies indicated a panel approach is indeed favourable, the Ubiquitous Pharmacogenomics Consortium recently completed the PREemptive Pharmacogenomic testing for prevention of Adverse drug Reactions (PREPARE) study. In this presentation, the results and experiences from PREPARE as well as the next steps for moving PGx testing from promise to practice will be discussed.

Learning Objectives

1. Describe the Dutch Pharmacogenetics Working Group Guidelines and how they support PGx testing
2. Recognise the efforts and results of the Ubiquitous Pharmacogenomics (www.upgx.eu) consortium to implement PGx testing in Europe
3. Identify how panel-based PGx testing may help to reduce the risk for adverse drug events